News

Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Asian shares slide and US futures and dollar drop after Wall Street's winning week
HONG KONG (AP) — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the ...
Investing4d
Novo Nordisk files for FDA approval of oral obesity drug - BioPharma Dive
Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...
US stocks power within 3% of their record as Wall Street closes out a winning week
On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...
Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...
Novo Nordisk CEO steps down as Wegovy maker faces increased competition
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...
Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.
It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...